The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Jianshu Liu - One of the best experts on this subject based on the ideXlab platform.
-
Suppressive Effect of Leukotriene Antagonists on Capsular Contracture in Patients Who Underwent Breast Surgery with Prosthesis: A Meta-Analysis.
Plastic and reconstructive surgery, 2020Co-Authors: Yuanliang Wang, Jing Tian, Jianshu LiuAbstract:Capsular contracture is a troublesome and distressing complication in mammaplasty or breast reconstruction involving a prosthesis. Previous studies have indicated that Leukotriene Antagonists effectively reverse capsular contracture. However, this treatment method lacks comprehensive support from evidence-based medicine and remains considerably controversial. In this study, a meta-analysis was conducted to evaluate the therapeutic and preventive effects of Leukotriene Antagonists on capsular contracture in patients after breast prosthesis implantation. A comprehensive literature search was performed in English and Chinese databases. All clinical studies assessing the therapeutic and prophylactic effects of Leukotriene Antagonists on capsule contracture after breast prosthesis implantation were selected. Risk differences and 95 percent confidence intervals were applied as the final pooled statistics. A total of five eligible studies were included, involving 1710 breast prosthesis implantations. The final results indicated that Leukotriene Antagonists markedly inhibited capsular contracture formation, with statistical significance at 32.02 (p < 0.001) (pooled risk difference, 0.84; 95 percent CI, 0.79 to 0.89). In subgroup analysis, subgroups based on different Leukotriene Antagonists included the montelukast and zafirlukast groups, with significant pooled statistical levels of 19.34 (p < 0.001) and 79.48 (p < 0.001), respectively (montelukast: pooled risk difference, 0.83; 95 percent CI, 0.75 to 0.92; zafirlukast: pooled risk difference, 0.85; 95 percent CI, 0.83 to 0.87), indicating that both montelukast and zafirlukast were effective in inhibiting encapsulation. This meta-analysis demonstrated that Leukotriene Antagonists (montelukast and zafirlukast) have significant effects in treating and preventing capsular contracture. These medications should be administered in a reasonable and safe way. Further studies of clinical efficacy, duration, safety, and exact mechanism of Leukotriene Antagonists for periprosthetic capsular contracture are warranted.
-
Suppressive Effect of Leukotriene Antagonists on Capsular Contracture in Patients Who Underwent Breast Surgery with Prosthesis: A Meta-Analysis.
Plastic and reconstructive surgery, 2020Co-Authors: Yuanliang Wang, Jing Tian, Jianshu LiuAbstract:Background:Capsular contracture is a troublesome and distressing complication in mammaplasty or breast reconstruction involving a prosthesis. Previous studies have indicated that Leukotriene Antagonists effectively reverse capsular contracture. However, this treatment method lacks comprehensive supp
P. R. Bernstein - One of the best experts on this subject based on the ideXlab platform.
-
Chemistry and structure-activity relationships of Leukotriene receptor Antagonists. Discussion
American Journal of Respiratory and Critical Care Medicine, 1998Co-Authors: P. R. Bernstein, Drazen, DahlenAbstract:Several strategies have been employed by medicinal chemists in the design of potent and selective Leukotriene receptor Antagonists-Leukotriene structural analogs, FPL 55712 analogs, and random screening of corporate compound banks. Lead compounds were optimized, often through the exchange of ideas with groups working on other chemical series of Leukotriene Antagonists. Pranlukast can likely be traced to a lead compound identified by random screening that was initially modified by incorporating structural components present in FPL 55712. Montelukast originated from an early quinoline lead, which was modified with Leukotriene structural elements. Zafirlukast is based on a lead compound that incorporated structural components from both FPL 55712 and the Leukotrienes. Therefore, each medicinal chemistry strategy that was originally employed has successfully identified clinically effective Leukotriene receptor Antagonists. Bernstein PR. Chemistry and structure-activity relationships of Leukotriene receptor Antagonists.
-
Chemistry and structure--activity relationships of Leukotriene receptor Antagonists.
American journal of respiratory and critical care medicine, 1998Co-Authors: P. R. BernsteinAbstract:Several strategies have been employed by medicinal chemists in the design of potent and selective Leukotriene receptor Antagonists-Leukotriene structural analogs, FPL 55712 analogs, and random screening of corporate compound banks. Lead compounds were optimized, often through the exchange of ideas with groups working on other chemical series of Leukotriene Antagonists. Pranlukast can likely be traced to a lead compound identified by random screening that was initially modified by incorporating structural components present in FPL 55712. Montelukast originated from an early quinoline lead, which was modified with Leukotriene structural elements. Zafirlukast is based on a lead compound that incorporated structural components from both FPL 55712 and the Leukotrienes. Therefore, each medicinal chemistry strategy that was originally employed has successfully identified clinically effective Leukotriene receptor Antagonists.
Yuanliang Wang - One of the best experts on this subject based on the ideXlab platform.
-
Suppressive Effect of Leukotriene Antagonists on Capsular Contracture in Patients Who Underwent Breast Surgery with Prosthesis: A Meta-Analysis.
Plastic and reconstructive surgery, 2020Co-Authors: Yuanliang Wang, Jing Tian, Jianshu LiuAbstract:Capsular contracture is a troublesome and distressing complication in mammaplasty or breast reconstruction involving a prosthesis. Previous studies have indicated that Leukotriene Antagonists effectively reverse capsular contracture. However, this treatment method lacks comprehensive support from evidence-based medicine and remains considerably controversial. In this study, a meta-analysis was conducted to evaluate the therapeutic and preventive effects of Leukotriene Antagonists on capsular contracture in patients after breast prosthesis implantation. A comprehensive literature search was performed in English and Chinese databases. All clinical studies assessing the therapeutic and prophylactic effects of Leukotriene Antagonists on capsule contracture after breast prosthesis implantation were selected. Risk differences and 95 percent confidence intervals were applied as the final pooled statistics. A total of five eligible studies were included, involving 1710 breast prosthesis implantations. The final results indicated that Leukotriene Antagonists markedly inhibited capsular contracture formation, with statistical significance at 32.02 (p < 0.001) (pooled risk difference, 0.84; 95 percent CI, 0.79 to 0.89). In subgroup analysis, subgroups based on different Leukotriene Antagonists included the montelukast and zafirlukast groups, with significant pooled statistical levels of 19.34 (p < 0.001) and 79.48 (p < 0.001), respectively (montelukast: pooled risk difference, 0.83; 95 percent CI, 0.75 to 0.92; zafirlukast: pooled risk difference, 0.85; 95 percent CI, 0.83 to 0.87), indicating that both montelukast and zafirlukast were effective in inhibiting encapsulation. This meta-analysis demonstrated that Leukotriene Antagonists (montelukast and zafirlukast) have significant effects in treating and preventing capsular contracture. These medications should be administered in a reasonable and safe way. Further studies of clinical efficacy, duration, safety, and exact mechanism of Leukotriene Antagonists for periprosthetic capsular contracture are warranted.
-
Suppressive Effect of Leukotriene Antagonists on Capsular Contracture in Patients Who Underwent Breast Surgery with Prosthesis: A Meta-Analysis.
Plastic and reconstructive surgery, 2020Co-Authors: Yuanliang Wang, Jing Tian, Jianshu LiuAbstract:Background:Capsular contracture is a troublesome and distressing complication in mammaplasty or breast reconstruction involving a prosthesis. Previous studies have indicated that Leukotriene Antagonists effectively reverse capsular contracture. However, this treatment method lacks comprehensive supp
Anthony P Sampson - One of the best experts on this subject based on the ideXlab platform.
-
Leukotriene Antagonists and synthesis inhibitors: New directions in asthma therapy
The Journal of allergy and clinical immunology, 1996Co-Authors: Stephen T. Holgate, Peter Bradding, Anthony P SampsonAbstract:Abstract This article briefly reviews the advances in our understanding of asthma with a particular focus on the role of inflammation, before providing a concise overview of current knowledge of Leukotrienes in the pathophysiology of the disease. The development of Leukotriene receptor Antagonists and synthesis inhibitors is briefly described; and acute exercise, allergen, and aspirin challenge studies with these agents are reviewed. Clinical studies with Leukotriene Antagonists and inhibitors have confirmed the central role of Leukotrienes in asthma pathophysiology. In conclusion, we suggest that the new generation of Leukotriene receptor Antagonists may be suitable as first-line therapy in patients with mild to moderate asthma. Further studies are required to determine whether the Leukotriene synthesis inhibitors will be equally effective or provide any additional antiinflammatory benefit. (J ALLERGY CLIN IMMUNOL 1996;98:1-13.)
Barbara A Muller - One of the best experts on this subject based on the ideXlab platform.
-
urticaria and angioedema a practical approach
South African Family Practice, 2005Co-Authors: Barbara A Muller, A LucilleAbstract:Urticaria (i.e., pruritic, raised wheals) and angioedema (i.e., deep mucocutaneous swelling) occur in up to 25 percent of the U.S. population. Vasoactive mediators released from mast cells and basophils produce the classic wheal and flare reaction. Diagnosis can be challenging, especially if symptoms are chronic or minimally responsive to therapy. A thorough medical history, physical examination, and methodical investigation are necessary to uncover diagnostic clues. Although serious medical illness can occur concurrently with chronic urticaria, acute urticaria generally is benign and self-limited. The mainstay of therapy for urticaria is avoidance of known triggering agents, judicious use of oral corticosteroids, and treatment with long-acting second-generation antihistamines, H 2 -receptor Antagonists, tricyclic antidepressants, and antiinflammatory Leukotriene Antagonists. Consultation for investigative therapy may be necessary if symptoms continue despite a stepwise approach to diagnosis and therapy. South African Family Practice Vol. 47(7) 2005: 20-23
-
urticaria and angioedema a practical approach
American Family Physician, 2004Co-Authors: Barbara A MullerAbstract:Urticaria (i.e., pruritic, raised wheals) and angioedema (i.e., deep mucocutaneous swelling) occur in up to 25 percent of the U.S. population. Vasoactive mediators released from mast cells and basophils produce the classic wheal and flare reaction. Diagnosis can be challenging, especially if symptoms are chronic or minimally responsive to therapy. A thorough medical history, physical examination, and methodical investigation are necessary to uncover diagnostic clues. Although serious medical illness can occur concurrently with chronic urticaria, acute urticaria generally is benign and self-limited. The mainstay of therapy for urticaria is avoidance of known triggering agents, judicious use of oral corticosteroids, and treatment with long-acting second-generation antihistamines, H2-receptor Antagonists, tricyclic antidepressants, and anti-inflammatory Leukotriene Antagonists. Consultation for investigative therapy may be necessary if symptoms continue despite a stepwise approach to diagnosis and therapy.